frontotemporal dementia

News

Alector ditches GSK-partnered dementia drug and cuts staff

Alector has abandoned latozinemab as a treatment for frontotemporal dementia, four years after GSK licensed the antibody in a $700m upfront deal.

News

Prof Vanessa Raymont of the University of Oxford

UK sets aside £2m for digitally-enhanced dementia tests

The UK is providing £2m in funding to allow digital assessment to be added to a highly-anticipated trial of blood tests for diagnosing dementia.

News

AviadoBio chief executive Lisa Deschamps

Astellas places $2bn+ bet on AviadoBio dementia gene therapy

Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic form of dementia from UK biotech AviadoBio for around $50 million.

Alector ditches GSK-partnered dementia drug and cuts staff

UK sets aside £2m for digitally-enhanced dementia tests

Astellas places $2bn+ bet on AviadoBio dementia gene therapy

ADARx, Trex, and Retension take aim at IPOs

Discover a new era of healthcare panel engagement: Grounded ...

frontotemporal dementia

Editor's Picks